Literature DB >> 31187090

The use of research biopsies in oncology trials: challenges and controversies.

Katherine V Ferry-Galow1, Alice P Chen2.   

Abstract

Entities:  

Year:  2019        PMID： 31187090      PMCID： PMC6557427          DOI： 10.21037/jhmhp.2019.03.01

Source DB:  PubMed          Journal:  J Hosp Manag Health Policy        ISSN： 2523-2533


× No keyword cloud information.
  12 in total

1.  A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors.

Authors:  Rebecca Kristeleit; Geoffrey I Shapiro; Howard A Burris; Amit M Oza; Patricia LoRusso; Manish R Patel; Susan M Domchek; Judith Balmaña; Yvette Drew; Lee-May Chen; Tamar Safra; Ana Montes; Heidi Giordano; Lara Maloney; Sandra Goble; Jeff Isaacson; Jim Xiao; Jen Borrow; Lindsey Rolfe; Ronnie Shapira-Frommer
Journal:  Clin Cancer Res       Date:  2017-03-06       Impact factor: 12.531

2.  Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.

Authors:  Randy F Sweis; Michael W Drazer; Mark J Ratain
Journal:  J Clin Oncol       Date:  2015-12-14       Impact factor: 44.544

3.  Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Sai-Hong I Ou; Yung-Jue Bang; D Ross Camidge; Benjamin J Solomon; Ravi Salgia; Gregory J Riely; Marileila Varella-Garcia; Geoffrey I Shapiro; Daniel B Costa; Robert C Doebele; Long Phi Le; Zongli Zheng; Weiwei Tan; Patricia Stephenson; S Martin Shreeve; Lesley M Tye; James G Christensen; Keith D Wilner; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2014-09-27       Impact factor: 91.245

4.  Theory and practice of clinical pharmacodynamics in oncology drug development.

Authors:  Ralph E Parchment; James H Doroshow
Journal:  Semin Oncol       Date:  2016-07-26       Impact factor: 4.929

5.  Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels.

Authors:  Philipp Mertins; Feng Yang; Tao Liu; D R Mani; Vladislav A Petyuk; Michael A Gillette; Karl R Clauser; Jana W Qiao; Marina A Gritsenko; Ronald J Moore; Douglas A Levine; Reid Townsend; Petra Erdmann-Gilmore; Jacqueline E Snider; Sherri R Davies; Kelly V Ruggles; David Fenyo; R Thomas Kitchens; Shunqiang Li; Narciso Olvera; Fanny Dao; Henry Rodriguez; Daniel W Chan; Daniel Liebler; Forest White; Karin D Rodland; Gordon B Mills; Richard D Smith; Amanda G Paulovich; Matthew Ellis; Steven A Carr
Journal:  Mol Cell Proteomics       Date:  2014-04-09       Impact factor: 5.911

6.  Ethical aspects of participation in the database of genotypes and phenotypes of the National Center for Biotechnology Information: the Cancer and Leukemia Group B Experience.

Authors:  Jeffrey Peppercorn; Iuliana Shapira; Teressa Deshields; Deanna Kroetz; Paula Friedman; Patricia Spears; Deborah E Collyar; Lawrence N Shulman; Lynn Dressler; Monica M Bertagnolli
Journal:  Cancer       Date:  2012-03-13       Impact factor: 6.860

Review 7.  The root causes of pharmacodynamic assay failure.

Authors:  Katherine V Ferry-Galow; Hala R Makhlouf; Deborah F Wilsker; Scott M Lawrence; Thomas D Pfister; Allison M Marrero; Kristina M Bigelow; William H Yutzy; Jiuping J Ji; Donna O Butcher; Brad A Gouker; Shivaani Kummar; Alice P Chen; Robert J Kinders; Ralph E Parchment; James H Doroshow
Journal:  Semin Oncol       Date:  2016-06-15       Impact factor: 4.929

8.  Publication and reporting conduct for pharmacodynamic analyses of tumor tissue in early-phase oncology trials.

Authors:  Georgina A Freeman; Jonathan Kimmelman
Journal:  Clin Cancer Res       Date:  2012-08-21       Impact factor: 12.531

9.  Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.

Authors:  Apurva K Srivastava; Melinda G Hollingshead; Jennifer Weiner; Tony Navas; Yvonne A Evrard; Sonny A Khin; Jiuping Jay Ji; Yiping Zhang; Suzanne Borgel; Thomas D Pfister; Robert J Kinders; Donald P Bottaro; W Marston Linehan; Joseph E Tomaszewski; James H Doroshow; Ralph E Parchment
Journal:  Clin Cancer Res       Date:  2016-03-21       Impact factor: 12.531

10.  Nanoproteomic analysis of ischemia-dependent changes in signaling protein phosphorylation in colorectal normal and cancer tissue.

Authors:  Florian T Unger; Nicole Lange; Jana Krüger; Carolyn Compton; Helen Moore; Lokesh Agrawal; Hartmut Juhl; Kerstin A David
Journal:  J Transl Med       Date:  2016-01-08       Impact factor: 5.531
View more
  2 in total

1.  Practical consideration for successful sequential tumor biopsies in first-in-human trials.

Authors:  Takafumi Koyama; Toshio Shimizu; Jun Sato; Yuki Katsuya; Satoru Iwasa; Shunsuke Kondo; Tatsuya Yoshida; Kazuki Sudo; Makoto Nishino; Yuichi Takiguchi; Kan Yonemori; Noboru Yamamoto
Journal:  Invest New Drugs       Date:  2022-04-11       Impact factor: 3.651

2.  Fine-needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next-generation sequencing in cancer patients included in the SHIVA02 trial.

Authors:  Célia Dupain; Julien Masliah-Planchon; Céline Gu; Elodie Girard; Pierre Gestraud; Pauline Du Rusquec; Edith Borcoman; Diana Bello; Francesco Ricci; Ségolène Hescot; Marie-Paule Sablin; Patricia Tresca; Alexandre de Moura; Delphine Loirat; Maxime Frelaut; Anne Vincent-Salomon; Charlotte Lecerf; Céline Callens; Samantha Antonio; Coralie Franck; Odette Mariani; Ivan Bièche; Maud Kamal; Christophe Le Tourneau; Vincent Servois
Journal:  Mol Oncol       Date:  2020-09-15       Impact factor: 6.603
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.